Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Update

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) saw a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 2,400 shares, a drop of 55.6% from the February 28th total of 5,400 shares. Based on an average trading volume of 6,700 shares, the short-interest ratio is currently 0.4 days.

Santen Pharmaceutical Price Performance

OTCMKTS:SNPHY opened at $9.66 on Friday. Santen Pharmaceutical has a one year low of $8.65 and a one year high of $13.00. The company’s 50-day simple moving average is $9.58 and its 200 day simple moving average is $10.66.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.